TA155
Choice of anti VEGF agents for wet AMD treatments
Dec 22
2014
College statement on choice of two antiVEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). March2014
College statement on choice of two antiVEGF agents for the treatment of wet AMD, following NICE guidance on Ranibizumab (TA155) and Aflibercept (TA294). March2014